New drug BI 3031185 tested for safety in BPD and ADHD patients
NCT ID NCT07001475
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 25 times
Summary
This study is testing a new medicine called BI 3031185 in adults with borderline personality disorder (BPD) or attention-deficit/hyperactivity disorder (ADHD). The main goal is to see how safe and tolerable the drug is when given as a single dose. Participants are randomly assigned to receive either the drug or a placebo, then switch after a two-week break. The study involves about 96 people and lasts 1 to 2 months, with regular health checks and monitoring for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATTENTION DEFICIT HYPERACTIVITY DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charité Research Organisation GmbH
RECRUITINGBerlin, 10117, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Martin-Luther-Universität Halle-Wittenberg
RECRUITINGHalle, 06112, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Medizinische Hochschule Hannover
NOT_YET_RECRUITINGHanover, 30625, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rheinhessen-Fachklinik Mainz
RECRUITINGMainz, 55122, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Technische Universität Dresden
NOT_YET_RECRUITINGDresden, 01307, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Bonn AöR
RECRUITINGBonn, 53127, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Frankfurt
RECRUITINGFrankfurt am Main, 60590, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Hamburg, Eppendorf
NOT_YET_RECRUITINGHamburg, 20251, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Leipzig
NOT_YET_RECRUITINGLeipzig, 04103, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Tübingen
RECRUITINGTübingen, 72076, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zentralinstitut für seelische Gesundheit
RECRUITINGMannheim, 68159, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zentrum Fuer Integrative Psychiatrie ZIP gGmbH Praevention-Therapie-Rehabilitation
NOT_YET_RECRUITINGKiel, 24105, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.